Effect of tocopherol conjugation on polycation-mediated siRNA delivery to orthotopic pancreatic tumors
Source abstract
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of cancer with a five-year survival rate of around 10 %. CXCR4 and STAT3 display crucial effects on proliferation, metastasis, angiogenesis, and formation of immunosuppressive microenvironment in pancreatic tumors. Here, we have tested the hypothesis that conjugation of α-tocopherol (TOC) to a polycation (PAMD), synthesized from CXCR4-antagonist AMD3100, will improve delivery of therapeutic siRNA to silence STAT3 in PDAC tumors. PAMD-TOC/siSTAT3 nanoparticles showed superior anti-cancer and anti-migration performance compared to the parent PAMD/siSTAT3 nanoparticles in both murine and human PDAC cell lines. The biodistribution of the nanoparticles in orthotropic mouse KPC8060 and human PANC-1 models, indicated that tumor accumulation of PAMD-TOC/siRNA nanoparticles was improved greatly as compared to PAMD/siRNA nanoparticles. This improved cellular uptake, penetration, and tumor accumulation of PAMD-TOC/siSTAT3 nanoparticles, also contributed to the suppression of tumor growth, metastasis and improved survival. Overall, this study presents a prospective treatment strategy for PDAC.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: MicroRNA in disease regulation · Cancer Cells and Metastasis · Phagocytosis and Immune Regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Cancer statistics, 2021
2. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990–201010.3748/wjg.v17.i7.867 ↗
3. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes10.3748/wjg.v24.i43.4846 ↗
4. Early detection of pancreatic cancer: opportunities and challenges10.1053/j.gastro.2019.01.259 ↗
5. Symptom management in pancreatic cancer10.1007/s11864-020-00801-4 ↗
6. Pancreatic cancer10.1016/S0140-6736(20)30974-0 ↗
7. Pancreatic cancer10.1016/S0140-6736(16)00141-0 ↗
8. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches10.1186/s13014-019-1345-6 ↗
9. Advanced-stage pancreatic cancer: therapy options10.1038/nrclinonc.2013.66 ↗
10. Management problems in patients with pancreatic cancer from a surgeon's perspective10.1053/j.seminoncol.2021.02.008 ↗
11. Regulation of tumor microenvironment for pancreatic cancer therapy10.1016/j.biomaterials.2021.120680 ↗
12. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential10.7150/thno.4922 ↗
13. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer10.1186/s12885-016-2143-2 ↗
14. Prognosis and clinicopathology of CXCR4 in colorectal cancer patients: a meta-analysis10.7314/APJCP.2015.16.9.4077 ↗
15. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy10.1016/j.pharmthera.2017.05.012 ↗
16. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial–mesenchymal transition in vitro through non-canonical activation of hedgehog pathway10.1016/j.canlet.2012.02.035 ↗
17. Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer
18. Effect of CXCL12 and its receptors on unpredictable renal cell carcinoma10.1016/j.clgc.2019.11.004 ↗
19. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies10.1016/j.semcancer.2019.12.007 ↗
20. The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer
21. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy10.1016/j.imlet.2019.11.007 ↗
22. Knockdown of CXCR4 inhibits CXCL12-induced angiogenesis in HUVECs through downregulation of the MAPK/ERK and PI3K/AKT and the Wnt/β-catenin pathways10.1080/07357907.2017.1422512 ↗
23. CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy10.1038/sj.bjc.6605968 ↗
24. Intraperitoneal siRNA nanoparticles for augmentation of gemcitabine efficacy in the treatment of pancreatic cancer10.1021/acs.molpharmaceut.1c00653 ↗
25. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer10.1126/science.1171362 ↗
26. Targeting the IL-6/JAK/STAT3 signalling axis in cancer10.1038/nrclinonc.2018.8 ↗
27. STAT3 as an emerging molecular target in pancreatic cancer
28. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression10.1016/j.ccr.2011.03.002 ↗
29. Role of STAT3 signaling pathway in breast cancer10.1186/s12964-020-0527-z ↗
30. The JAK/STAT3 axis: a comprehensive drug target for solid malignancies10.1016/j.semcancer.2017.06.001 ↗
31. Novel activators and small-molecule inhibitors of STAT3 in cancer10.1016/j.cytogfr.2019.10.005 ↗
32. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer10.1016/j.ccr.2011.03.009 ↗
33. STAT3 and apoptosis challenges in cancer10.1016/j.ijbiomac.2018.05.121 ↗
34. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis10.1038/sj.onc.1207383 ↗
35. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment10.1038/nri1995 ↗
36. STATs in cancer inflammation and immunity: a leading role for STAT310.1038/nrc2734 ↗
37. Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric plerixafor10.1016/j.biomaterials.2014.03.047 ↗
38. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting nanoparticles10.1039/C5BM00003C ↗
39. Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple miRNA/siRNA nanotherapy10.1021/acsnano.9b03978 ↗
40. Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer10.1016/j.jconrel.2021.03.028 ↗
41. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer10.1021/mp100012s ↗
42. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice10.1016/j.ijpharm.2015.09.030 ↗
43. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol10.1038/mt.2008.14 ↗
44. Chimeric antisense oligonucleotide conjugated to α-tocopherol
45. Nucleic acid delivery with α-tocopherol-polyethyleneimine-polyethylene glycol nanocarrier system10.2147/IJN.S259724 ↗
46. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol10.1038/mt.2008.14 ↗
47. Polymeric plerixafor: effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection10.1007/s11095-014-1440-1 ↗
48. Development of α-tocopherol surface-modified targeted delivery of 5-fluorouracil-loaded poly-D,L-lactic-co-glycolic acid nanoparticles against oral squamous cell carcinoma10.4103/jcrt.JCRT_263_18 ↗
49. Tocopheryl oligochitosan-based self assembling oligomersomes for siRNA delivery10.1016/j.biomaterials.2010.09.027 ↗
50. Nanoemulsion-assisted siRNA delivery to modulate the nervous tumor microenvironment in the treatment of pancreatic cancer10.1021/acsami.1c21997 ↗
51. STAT3 down-regulation induces mitochondria-dependent G2/M cell cycle arrest and apoptosis in oesophageal carcinoma cells10.1111/1440-1681.12708 ↗
52. CXCR4 promotes neuroblastoma growth and therapeutic resistance through miR-15a/16-1-mediated ERK and BCL2/Cyclin D1 pathways10.1158/0008-5472.CAN-17-0454 ↗
53. Targeting STAT3 in cancer immunotherapy10.1186/s12943-020-01258-7 ↗
54. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer10.1073/pnas.1815515116 ↗
55. Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival10.1053/j.gastro.2016.03.010 ↗